Peripheral blood mononuclear cells of 10 out of 26 patients with human immunodeficiency virus type 1 (HIV-1) released IgE-binding factors, as determined by two independent assays. The formation of the factors by the mononudear cells was enhanced by incubation of the cells with homologous IgE. In the presence of IgE, peripheral blood mononuclear cells from 15 of the 26 patients formed a detectable amount of IgE-binding factors, whereas those of normal individuals or allergic rhinitis patients failed to do so. The major source of IgE-binding factors was the T cells of the HIV-1-infected patients. The CD8 + T cells from a HIV-1-infected patient formed IgE-binding factors upon incubation with IgE, and type II receptors for FcE were detected on both CD4' T cells and CD8' T cells in one of five patients studied.
It was also found that culture supernatants of mononuclear cells from HIV-1-infected patients released soluble factors that induce normal human T cells to form IgE-binding factors. The results suggest that lymphocytes of some HIV-1-infected patients are activated to produce lymphokines regulating formation of IgE-binding factors.
Previous experiments have shown that peripheral blood mononuclear cells (PBMCs) from ragweed-sensitive allergic individuals released soluble factors having affinity for IgE when the cells were incubated with allergen together with human IgE (1) . Activation of normal PBMCs with phytohemagglutinin followed by incubation of the activated T cells with IgE also induced the formation of IgE-binding factors (IgE-BF). Young et al. (2) established FcE receptor-positive (FcR+) human T-cell clones from a patient with atopic dermatitis and found that these clones released IgE-BF.
Nagai et al. (3) demonstrated FceR' cells from patients with Kimura disease. Subsequently, the human B-cell Fc8R gene was cloned and found to hybridize to mRNA from normal B cells, macrophages, and eosinophils, but not to mRNA from normal T cells (4) . However, the FceR mRNA was detected in T-cell lines transformed with human T-lymphotropic virus type I (HTLV-I) (5) . Indeed, FcR and IgE-BF from a HTLV-I-transformed T-cell line have been identified by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (6) . In view of the similar tropism of the retroviruses HTLV-I and human immunodeficiency virus type 1 (HIV-I), these findings suggested to us the possibility that T cells of HIV-1-infected patients as well may form IgE-BF. The present experiments were undertaken to study that possibility. The results show that T cells from many patients with HIV-1 infection form IgE-BF and that the formation of the factors is enhanced by incubation of the cells with homologous IgE. These results have been presented in part. ¶ MATERIALS AND METHODS Source of PBMCs. We studied 35 HIV-1-infected patients-5 with acquired immunodeficiency syndrome (AIDS), 9 with AIDS-related complex (ARC), 9 with lymphadenopathy syndrome (LAS), and 12 who were seropositive but asymptomatic-as well as 5 normal individuals and 2 patients who had allergic rhinitis. Mononuclear cells were obtained from their peripheral blood by centrifugation on Ficoll/Hypaque (Pharmacia). Immunofluorescence analysis of the mononuclear cells from the HIV-1-infected individuals showed that the ratio of CD4' T cells to CD8' T cells was between 0.1 and 0.6, substantially lower than in normal individuals (normal range 1.0-2.5).
Immunoglobulins. E myeloma protein was isolated from the serum of an E myeloma patient, PS, by the method previously described (7) . The purity of the preparation was >99.7%. Dimeric human IgE was the same preparation as that described in a previous article (8) . IgE dimer was labeled with 1251I by the chloramine-T method; 100 ,ug of the protein was labeled with 1 mCi of 1251I (1 Ci = 37 GBq). Human IgE was coupled to Sepharose CL-4B (Pharmacia); =5 mg of the protein were coupled to 1 ml of Sepharose. Monoclonal antibody specific for Fc6RII on human B lymphocytes was obtained from ascitic fluids of BALB/c nude mice bearing the B-cell hybridoma H107 (9) . The antibody preparation employed in the present experiments was the IgG fraction of the ascitic fluids. The fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin used in the indirect immunofluorescence was purchased from Tago (Burlingame, CA). Leu-2, Leu-3, Leu-4, and Leu-12 monoclonal antibodies were purchased from the Becton Dickinson Monoclonal Center. Recombinant human interleukin 4 (IL-4) was kindly supplied by N. Arai (DNAX Institute of Molecular Biology). Recombinant human y-interferon (IFN-y) was obtained from Schering.
Cell Cultures. Culture medium was RPMI-1640 medium supplemented with 10% fetal bovine serum (Flow Laboratories), 2 mM L-glutamine, and antibiotics. PBMCs or their fractions were suspended in the culture medium (0.5 x 106 cells per ml) in 24-well culture plates (Costar, Cambridge, MA) and cultured for 48 hr in the presence or absence of human IgE (10 ,ug/ml). The (8) . For the formation of IgE-BF, the hybridoma cells were suspended in RPMI-1640 culture medium (106 cells per ml), and the cell suspensions were incubated for 24 hr in the presence of human IgE dimer (50 ng/ml).
Cell Fractionation. PBMCs were fractionated into a T-cell enriched population and a B-cell-and monocyte-enriched population by rosette formation with aminoethylisothioronium-treated sheep erythrocytes, followed by centrifugation over Ficoll/Hypaque (10) . T cells were recovered from the pellet containing rosetted cells after lysing the red cells with buffered 0.87% NH4Cl. A T-cell-enriched fraction from one HIV-1-infected patient was further fractionated into CD8' cells and CD8-cells by positive selection of lymphocytes labeled with anti-Leu-2a, using magnetic beads coated with goat anti-mouse immunoglobulin (Dynel, Great Neck, NY) as described (11) .
Immunofluorescence. Proportions of B cells, T cells, and their subsets were determined by flow cytometry. Cells (2) (3) (4) (5) x 105) were incubated with 10 Al of the appropriate monoclonal antibody for 30 min at 40C. For analysis of B cells and T-cell subsets, antibodies conjugated directly to fluorescein isothiocyanate or phycoerythrin were used. After two washes with phosphate-buffered saline containing 1% bovine serum albumin and 0.1% sodium azide, cells were analyzed with an EPICS-C flow cytometer (Coulter) equipped with software for two-color analysis. For the detection of FceR on subsets of T cells, T-cell-enriched fractions were incubated first with monoclonal antibody H107 and then with fluoresceinated F(ab')2 fragments of anti-mouse immunoglobulin (Tago) and phycoerythrin-labeled Leu-2 or Leu-3 antibody and were analyzed as above. Five thousand cells were analyzed in each determination.
Detection of IgE-BF. IgE-BF were affinity-purified by using IgE-Sepharose (12) . Culture supernatants ofPBMCs orT-cell hybridoma 166A2 cells were filtered through Diaflo YM100 membranes (Amicon), and the filtrates were concentrated 10-fold by ultrafiltration. One milliliter of the concentrated filtrate was adsorbed by mixing with 0.25 ml of IgE-coated Sepharose overnight at 4°C. The IgE-Sepharose was packed into a small column and was washed with 5 ml of Dulbecco's phosphate-buffered saline (DPBS). Bound material was then eluted with 1 ml of glycine/HCl buffer (pH 3.0). The eluates were immediately neutralized with Tris/HCl buffer and dialyzed against DPBS.
The presence of IgE-BF in the acid-eluate fractions from IgE-Sepharose was assessed by their ability to inhibit rosette formation of RPMI 8866 cells with fixed ox erythrocytes coated with human IgE (E'-IgE) (12) . To increase the sensitivity of the assay for rosette inhibition, E'-IgE were prepared by sensitizing fixed ox erythrocytes with 0.02 mg of human IgE per ml. With these indicator cells, 25-45% of RPMI 8866 cells formed rosettes. To detect IgE-BF in the eluate fraction from IgE-Sepharose, E'-IgE were preincubated with a sample to be tested, and RPMI 8866 cells were added to the suspension for rosette formation. The percentage of rosette inhibition was determined in duplicate slides and was expressed as the average. In view of experimental error (SD) in the proportion of rosette-forming cells in replicate slides, less than 8-10%o inhibition was taken as not significant.
We established a radioimmunoassay (RIA) for IgE-BF by using monoclonal antibody H107 which, crossreacts with T-cell-derived IgE-BF (13) . Wells of microtest flexible plates (Costar) were coated with 10 ,ug of the monoclonal antibody in 100 ,l of 0.1-M carbonate/bicarbonate buffer (pH 9.6). After coating overnight at 40C, wells were washed with DPBS and blocked with 2% bovine serum albumin. After washing with DPBS containing 0.05% Tween 20, samples (50 AL) were added to duplicate or triplicate wells and the plates were kept overnight at 40C. Wells were washed five times with DPBS containing 0.05% Tween 20, and 100 1.l of 1251I-labeled IgE dimer (-100,000 cpm, or 50 ng of protein) in DPBS containing 0.1% bovine serum albumin and 0.05% Tween 20 was added to each well. The plates were incubated again overnight at 40C and washed thoroughly with DPBS/Tween 20, and the radioactivity of each well was determined in an automatic y counter. Background count with DPBS, instead of a sample, was subtracted.
RESULTS
As a preliminary experiment, we determined whether IgE-BF from the T-cell hybridoma 166A2 can be detected by RIA. The hybridoma cells were cultured with IgE dimer or without IgE, and IgE-BF in culture filtrates were purified by using IgE-Sepharose. The eluates from IgE-Sepharose were concentrated to 1/10th the volume of the original culture supernatants, and the factors were titrated by radioimmunoassay (Fig. 1) . Titration of the same samples by rosette-inhibition assay indicated that IgE-BF was detected in a 1:8 dilution of the purified IgE-BF, but not in a 1:16 dilution. Culture filtrates of unstimulated T-cell hybridoma did not contain a detectable amount of IgE-BF, as determined by rosette inhibition, and gave 277 ± 21 cpm by RIA (Fig. 1) . Experiments were carried out to determine the level of nonspecific binding of 125I-labeled IgE dimer in the RIA. PBMCs of five normal individuals were cultured for 48 hr in the presence or absence of IgE. Culture filtrates were concentrated 10-fold and adsorbed with IgE-Sepharose, and proteins bound to IgE-Sepharose were eluted at acid pH. As expected, the acid-eluate fractions failed to inhibit IgE rosette formation and gave 215-308 (248 ± 45) cpm in the RIA.
We then determined the presence of IgE-BF in culture filtrates of PBMCs from HIV-i-infected patients. Among 26 cases in which the presence of IgE-BF in the acid-eluate fraction from IgE-Sepharose was examined by both rosette inhibition and RIA, IgE-BF were detected in filtrates of unstimulated cell cultures from 10 cases by both techniques. When samples from these cases were applied to H107-coated wells, the binding of 1251-labeled IgE dimer was more than twice that obtained with control preparations from normal PBMCs (Fig. 2) . The same samples inhibited IgE rosette formation between 13% and 27%. It was also found that the formation of IgE-BF markedly increased when the same cells were incubated with IgE. In the IgE-treated cultures, IgE-BF was detected in culture filtrates of PBMCs from 15 HIV-1-infected patients by both RIA and rosette inhibition.
We determined whether the IgE-BF was derived from T cells or B cells. PBMCs from a seropositive asymptomatic patient were fractionated, by rosetting with sheep erythrocytes, into a T-cell-enriched population and a T-cell-depleted population, and each population was cultured in the presence or absence of IgE. Immunofluorescence staining showed that 92% of the cells in the T-cell-enriched fraction were Leu-4+, whereas 78% of the cells in the T-cell-depleted fraction were positive for Leu-12, a B-cell marker. The T-cell-enriched fraction released IgE-BF, whereas the T-cell-depleted fraction did not (Table 1) . It was also found that incubation of the T-cell fraction with IgE enhanced the formation of IgE-BF. The results clearly show that T cells were the source of IgE-BF. A similar experiment with T cells and B cells from an AIDS patient confirmed the results.
An increase of IgE-BF formation by PBMCs upon incubation with IgE suggested that the T cells might bear Fc6R.
Thus, we obtained T-cell-enriched fractions from HIV-1-infected patients and stained the cells with either anti-Leu-2 or anti-Leu-3, together with anti-FcERII (H107). Cytofluorometric analysis of the double-stained cell preparations demonstrated that virtually all of the Leu-3+ cells from one patient were stained by H107 (Fig. 3) . Most of the Leu 2+ cells from this patient also expressed Fc6R (data not shown). (Fig. 2) , suggested to us the possibility that the CD8' T cells may form IgE-BF. Thus, a T-cell-enriched fraction ofa seropositive but asymptomatic HIV-1-infected patient was further fractionated into a CD8+-cell-enriched population and CD8+-cell-depleted population. The proportions of CD8' cells in the two fractions were 95% and 2.3%, respectively (Table 2) . Both fractions were cultured for 48 hr in the presence of IgE (10 ,ug/ml), and culture filtrates were assessed for IgE-BF. The results clearly showed that CD8+ T cells of this patient formed IgE-BF upon incubation with IgE. However, this finding does not exclude the possibility that Fc6RII+, CD4' T cells from other patients may form IgE-BF. In rodent systems, CD4' cells were the major cellular source of IgE-BF (14) .
The formation of IgE-BF by unstimulated T cells of some HIV-1-infected patients suggested that lymphocytes of these patients may release a lymphokine that induces normal lymphocytes to form IgE-BF. To test this possibility, PBMCs of six HIV-1-infected patients, one normal individual, and one atopic individual were cultured for 2 days. Previous experiments (Fig. 2) indicated that culture filtrates of PBMCs from four of the six HIV-1-infected patients contained a detectable amount of IgE-BF, while those from the other two patients and from the normal subject did not (Table 3 ). The culture filtrates were concentrated 10-fold by ultrafiltration, and 1 ml of each sample was adsorbed to IgE-Sepharose. The unbound protein fraction was then added to an equal volume of a suspension of normal T lymphocytes (2 x 106 nucleated cells per ml), and the cells were cultured for 2 days. The culture filtrates were concentrated 10-fold, and IgE-BF in the filtrates were assessed (Table 3) . Culture filtrates of mononuclear cells from four of the six HIV-1-infected patients (i.e., those whose lymphocytes constitutively released IgE-BF) could induce normal lymphocytes to produce IgE-BF.
IL-4 induces the biosynthesis and expression of FcR on B cells in both humans and rodents (15, 16) . Recent experiments with mouse splenic lymphocytes indicated that IFN-y induces the formation of IgE-BF by normal T cells (17) . To test the possibility that IL-4 or IFN-y may be involved in the induction of IgE-BF formation by T cells of HIV-1-infected (19) . In rodent systems, however, fragments of Fc6R on B cells failed to bind to IgE (20) . Blot hybridization with a human B-cell FceR cDNA revealed that mRNA for Fc6RII is undetectable in normal T cells but present in HTLV-I-transformed T-cell lines (5) . Several human T-cell hybridoma clones form IgE-BF upon incubation with IgE, or with monoclonal anti-Fc8R H107, but these cells were not stained by the antibody in immunofluorescence (13 It is not known why T cells of many HIV-1-infected patients formed IgE-BF. Considering that transformation of T cells with HTLV-I induces the expression of FceR, it is possible that infection with HIV-1 also induces the expression of the receptors. Another possibility is that the "IgE-BF" detected in the present experiments are related to retrovirus. The nucleotide sequence of a rodent IgE-BF gene is remarkably similar to that of a cloned mouse interacisternal A particle (21) . However, the possibility is unlikely because the targets of HIV-1 are CD4' T cells (22) tor(s) that induced normal T cells to form IgE-BF (Table 3) . It is known that IL-4 induces the synthesis of FcR in B cells and enhances the release of the fragments of FcR (15) . It has been found that IFN-y (25-50 units/ml) induces rodent T cells to form IgE-BF (17) . However, neither IL-4 (10 units/ml) nor IFN-y (25-50 units/ml) induces normal human T cells to form IgE-BF. Recently, Kawabe et al. (5) have shown that the HTLV-I-transformed T cell line EH constitutively forms IgE-BF but responds neither to IL-4 nor to IFN-y with enhanced biosynthesis of IgE-BF. In the mouse system, Marcelletti and Katz (23) reported that B cells form a soluble factor, EIRT, that induces the expression of Fc6RII on T cells. It is possible that the lymphokine formed by lymphocytes of HIV-1-infected patients corresponds to this factor. Identification of T-cell factors responsible for the formation of IgE-BF requires further studies. Nevertheless, the present findings suggest that a subset of T cells in HIV-1-infected patients is activated and releases a lymphokine responsible for the formation of IgE-BF.
AIDS is characterized by a polyclonal hypergammaglobulinemia, which generally involves immunoglobulins G, A, and M (24) . Of note, AIDS is also characterized by a high incidence of drug reactions and other clinical manifestations that resemble IgE-mediated hypersensitivity reactions (25) (26) (27) . Elevated levels of IgE have been reported in patients with AIDS, either with or without a previous history of atopy (27) . In the present study, four patients had elevated levels of IgE, only one of whom had a history suggesting atopy. These data, along with the frequent production of IgE-BF by the cultured PBMCs of HIV-1-infected individuals, raise the possibility that formation of IgE-regulatory T cell factor(s) could contribute to the frequency of adverse drug reactions that complicates treatment of AIDS patients.
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